Genzyme snaps up Bayer's MS and oncology drugs for $2.8 billion
This article was originally published in Scrip
Executive Summary
Genzyme is to spend up to $2.8 billion to acquire Bayer Healthcare's MS treatment Campath (alemtuzumab) and the anticancers Fludara (fludarabine) and Leukine (sargramostim). The deal will strengthen Genzyme's multiple sclerosis and haematologic oncology pipeline, and help it achieve 20% compound average non-GAAP earnings growth from 2006 to 2011.